Eric Hansen, DO
Family Medicine · Hesperia, CANPI 1770562506
Payments from drug & device makers
Across 211 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$500
- Novo Nordisk$329
- Boehringer Ingelheim$265
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$248
- Abbott$165
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,912100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 63 | $1,250 |
| GSK | 34 | $500 |
| Novo Nordisk | 27 | $329 |
| Boehringer Ingelheim | 12 | $265 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $248 |
| Abbott | 3 | $165 |
| Corcept Therapeutics | 8 | $142 |
| Stryker | 1 | $136 |
| Lilly USA, LLC | 7 | $131 |
| Pfizer | 7 | $122 |
| Merck | 7 | $118 |
| Novartis | 4 | $79 |
| AbbVie(2 entities) | 4 | $76 |
| Bayer | 4 | $67 |
| Sanofi-aventis U.S. LLC | 4 | $54 |
| Verona Pharma, Inc. | 2 | $44 |
| Gilead | 1 | $38 |
| Otsuka America Pharmaceutical, Inc. | 1 | $30 |
| Smith+Nephew | 2 | $29 |
| Ultragenyx Pharmaceutical Inc. | 1 | $25 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Exact Sciences | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JETI$129
How this compares
$3,927 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 205 | $154,672 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 224 | $149,608 |
| RybelsusSemaglutide | 82 | $98,319 |
| XareltoRivaroxaban | 44 | $49,360 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 73 | $48,409 |
| OzempicSemaglutide | 47 | $45,273 |
| JanuviaSitagliptin Phosphate | 46 | $42,269 |
| JardianceEmpagliflozin | 57 | $39,639 |
| EntrestoSacubitril/Valsartan | 52 | $36,297 |
| Breo ElliptaFluticasone/Vilanterol | 64 | $31,462 |
| FarxigaDapagliflozin Propanediol | 29 | $27,202 |
| TrulicityDulaglutide | 25 | $25,196 |
| KerendiaFinerenone | 11 | $11,019 |
| NeuproRotigotine | 12 | $9,612 |
| Levothyroxine Sodium | 923 | $8,123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $500 | $181,071288 claims |
| PfizerEliquis | $122 | $154,672205 claims |
| Novo NordiskRybelsus, Ozempic | $329 | $143,592129 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $1,250 | $79,785117 claims |
| MerckJanuvia, Belsomra | $118 | $50,05267 claims |
| Boehringer IngelheimJardiance | $265 | $39,63957 claims |
| NovartisEntresto | $79 | $36,29752 claims |
| Lilly USA, LLCTrulicity | $131 | $25,19625 claims |
| BayerKerendia | $67 | $11,01911 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $12 | $2,20111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.
Other family medicine in Hesperia
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.